Narrows FY23 revenue view to $15B-$15.4B from $14.8B-$15.4B, consensus $15.02B. Sees FY23 tax rate 14%-17%, with free cash flow of $1.7B-$2.1B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA:
- Teva Pharamceutical (NYSE:TEVA) Surges After Earnings Report
- Teva Pharmaceutical Industries Limited (TEVA) Q2 Earnings Cheat Sheet
- Mizuho biotech/biopharma analyst to hold analyst/industry conference call
- Teva, Alvotech to expand strategic biosimilars partnership agreement
- Exelixis announces settlement of CABOMETYX patent litigation with Teva